Document is current
Any future updates will be listed below
-
Authors
Hadj-Aissa, Imane https://orcid.org/0009-0003-0649-3264
Muller, Maéline https://orcid.org/0009-0004-2864-1894
Soliz, Jorge
Sephton, Chantelle F https://orcid.org/0000-0002-9839-0611
Dutchak, Paul A https://orcid.org/0000-0002-7965-8870
-
Funding
Funding for this research was provided by:
Natural Sciences and Engineering Research Council of Canada (RGPIN-2018-06227)
Natural Sciences and Engineering Research Council of Canada (DGECR-2018-00093)
Natural Sciences and Engineering Research Council of Canada (RGPIN-2020-06376)
Natural Sciences and Engineering Research Council of Canada (DGECR-2020-00060)
Brain Canada Foundation (Future Leaders in Canadian Brain Research program.)
Canadian Institutes of Health Research (202409PJT-526975)
Canadian Institutes of Health Research (202309PJT-506236)
Canadian Institutes of Health Research (IC135391)
- License Information
-
More Information
Article History
Received: 1 October 2025
Revised: 27 April 2026
Accepted: 10 June 2026
First Online: 3 July 2026
Disclosure and competing interests statement
: PAD is an inventor on a university-owned patent application related to mTORC1-targeting antisense oligonucleotides. The intellectual property is owned and managed by Université Laval and is not directly examined in this study. The authors declare no competing interests.
